A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

• Status: Recruiting
• Trial end date: 2024-12-30

Summary

The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients who have progressed extracranially following first-line osimertinib treatment.

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel
• Treatments: Carboplatin; Cisplatin; Osimertinib; Pemetrexed